BioSymetrics, a biomedical artificial intelligence company has entered a collaboration with Sema4, a patient-centered health intelligence company, and Janssen Pharmaceuticals, Inc. The collaboration will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.
The parties will use BioSymetrics’ Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.
“We’ve been working on deploying AI in the clinical setting for several years,” said Anthony Iacovone, Co-Founder and Chairman of BioSymetrics. “We’ve demonstrated that machine learning can bring speed and precision to helping identify at risk patient populations, predict disease outcomes, and build better treatments, but the pandemic has now pushed biomedical AI technology to the fore front of innovative necessity.”
Eric Schadt, Founder and CEO of Sema4 added: “There is dramatic heterogeneity within the COVID-19 patient groups and a spectrum of disease risk that must be interpreted probabilistically – something of which I believe this collaboration will drive through innovation and combined expertise.”
BioSymetrics’ platform uses an AI iteration framework that can be used in conjunction with clinical research to predict target mechanism, identify lead compounds, or provide clinical insights. The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against SARS-CoV-2.